Corynebacterium propinquum

I. Taxonomic Position and Basic Characteristics

Corynebacterium propinquum belongs to the phylum Actinobacteria, family Corynebacteriaceae, genus Corynebacterium. It is a Gram-positive, non-motile, non-spore-forming bacillus displaying marked pleomorphism. Cells typically appear as straight or slightly curved rods with club-shaped ends and may arrange in V-shaped or palisading patterns.

The organism is facultatively anaerobic and nutritionally demanding. On blood agar, it grows slowly, forming small, gray-white, non-hemolytic colonies. Biochemically, it ferments multiple carbohydrates with acid production and is characteristically pyrazinamidase-positive while usually urease- and nitrate reduction–negative, features that aid laboratory differentiation from related corynebacterial species.

II. Ecological Distribution and Pathogenic Potential

C. propinquum is a common member of the normal microbiota of the human upper respiratory tract, particularly the nasopharynx and oropharynx, and may also be detected on the skin. In healthy individuals, colonization is typically asymptomatic.

It is classified as an opportunistic pathogen. When host defenses are compromised, the bacterium may proliferate excessively or invade sterile sites. Its pathogenicity is associated with biofilm formation, adhesion to host tissues or medical devices, and the induction of exaggerated inflammatory responses under favorable conditions.

III. Clinical Manifestations and High-Risk Populations

Infections caused by C. propinquum are usually endogenous. Although uncommon, they may be severe in vulnerable populations.

High-risk groups include immunocompromised patients, individuals with severe underlying diseases, and those undergoing invasive medical procedures or long-term hospitalization.

IV. Antimicrobial Susceptibility and Treatment Considerations

C. propinquum generally remains susceptible to β-lactam antibiotics, including penicillin G, ampicillin, and early-generation cephalosporins. Most isolates are also highly susceptible to vancomycin, which serves as a reliable option for severe infections or β-lactam–allergic patients.

For confirmed systemic infections such as bacteremia or endocarditis, therapy should be guided by antimicrobial susceptibility testing and administered intravenously for an adequate duration (typically 4–6 weeks for endocarditis). Removal of infected indwelling devices is often critical for successful treatment.

V. Diagnostic Challenges and Molecular Detection

Because C. propinquum is part of the normal respiratory flora, isolation from non-sterile specimens such as sputum or throat swabs is usually not clinically significant. Definitive diagnosis relies on detection from sterile sites or strong correlation with clinical findings.

Traditional culture and biochemical identification are time-consuming and may lead to misidentification. Modern approaches, including MALDI-TOF MS, 16S rRNA gene sequencing, and species-specific real-time PCR, provide faster and more accurate identification.

VI. Summary

Corynebacterium propinquum exemplifies the transition from a harmless commensal to a clinically relevant opportunistic pathogen. While its intrinsic virulence is limited, it can cause serious infections in immunocompromised hosts or patients with implanted medical devices. Accurate species-level identification and appropriate antimicrobial therapy are essential for optimal clinical management. The application of molecular diagnostic tools further enhances our ability to recognize and control infections caused by this often-overlooked bacterium.